Imunon Inc
IMNN1.140USD
+0.724+174.37%
Cierre 05/23, 16:00（ET）Cotizaciones retrasadas 15 min
16.67MCap. mercado
PérdidaP/E TTM
Más Datos de Imunon Inc Compañía
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Información de la empresa
Código de la empresaIMNN
Nombre de la empresaImunon Inc
Fecha de salida a bolsaOct 27, 1993
Fundada en2000
Director ejecutivoDr. Stacy R. Lindborg, Ph.D.
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 27
Dirección997 Lenox Dr Ste 100
CiudadLAWRENCEVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08648
Teléfono16098969100
Sitio Webhttps://imunon.com/
Código de la empresaIMNN
Fecha de salida a bolsaOct 27, 1993
Fundada en2000
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David (Dave) Gaiero, CPA
Mr. David (Dave) Gaiero, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
69.14K
+66.55%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
25.60K
--
Dr. Sebastien Hazard
Dr. Sebastien Hazard
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
20.00K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
12.86K
+350.26%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
11.77K
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: vie., 16 de may
Hora de actualización: vie., 16 de may
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Estadísticas de accionistas
Accionista
Proporción
Geode Capital Management, L.L.C.
0.98%
Tardugno (Michael H)
0.47%
BlackRock Institutional Trust Company, N.A.
0.40%
Le (Goff Corinne)
0.36%
The Vanguard Group, Inc.
0.33%
Other
97.45%
Tipo
Accionista
Proporción
Investment Advisor/Hedge Fund
1.68%
Individual Investor
1.52%
Investment Advisor
0.41%
Venture Capital
0.15%
Hedge Fund
0.10%
Other
96.14%
Participación institucional
Hora de actualización: lun., 3 de mar
Hora de actualización: lun., 3 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
49
648.18K
4.43%
-1.83M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
2023Q1
80
515.97K
6.03%
-572.90K
2022Q4
81
529.26K
7.22%
-671.21K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Geode Capital Management, L.L.C.
139.50K
0.95%
+13.57K
+10.78%
Dec 31, 2024
Tardugno (Michael H)
69.14K
0.47%
+27.63K
+66.55%
Feb 21, 2025
BlackRock Institutional Trust Company, N.A.
58.22K
0.4%
--
--
Dec 31, 2024
Le (Goff Corinne)
53.00K
0.36%
--
--
Feb 21, 2025
The Vanguard Group, Inc.
48.81K
0.33%
--
--
Dec 31, 2024
Lindborg (Stacy R. Ph.D.)
28.06K
0.19%
+3.06K
+12.22%
Feb 21, 2025
Braun (Donald P)
25.60K
0.18%
--
--
Feb 21, 2025
XTX Markets LLC
21.41K
0.15%
+21.41K
--
Dec 31, 2024
Northern Trust Investments, Inc.
21.64K
0.15%
+18.40K
+567.70%
Dec 31, 2024
State Street Global Advisors (US)
21.30K
0.15%
--
--
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: mar., 6 de may
Hora de actualización: mar., 6 de may
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Fecha
Tipo
Relación
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
Feb 28, 2022
Merger
15<1
